My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
2024_OpioidSettlemtAgrmt_JanssenJJ
>
Meetings
>
2024
>
04. April
>
2024-04-16 10:00 AM - Commissioners' Agenda
>
2024_OpioidSettlemtAgrmt_JanssenJJ
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
4/11/2024 1:10:33 PM
Creation date
4/11/2024 1:08:48 PM
Metadata
Fields
Template:
Meeting
Date
4/16/2024
Meeting title
Commissioners' Agenda
Location
Commissioners' Auditorium
Address
205 West 5th Room 109 - Ellensburg
Meeting type
Regular
Meeting document type
Supporting documentation
Supplemental fields
Item
Request to Approve a Resolution Accepting the Johnson & Johnson (Janssen) Washington State State-Wide Opioid Settlement Agreement
Order
7
Placement
Consent Agenda
Row ID
116716
Type
Agreement
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
127
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
<br />17 <br /> <br /> <br />For the Attorney General: <br /> <br />Jeffrey G. Rupert <br />Martha Rodríguez López <br />Susan Llorens <br />Office of the Washington Attorney General <br />800 Fifth Avenue, Suite 2000 <br />Seattle, WA 98104 <br />Jeffrey.Rupert@atg.wa.gov <br />Martha.RodriguezLopez@atg.wa.gov <br />Susan.Llorens@atg.wa.gov <br /> <br />and <br /> <br />Brad Beckworth <br />Drew Pate <br />Nix Patterson LLP <br />8701 Bee Caves Road, Building 1, Suite 500 <br />Austin, Texas 78746 <br />bbeckworth@nixlaw.com <br />dpate@nixlaw.com <br /> <br />Any Party may change or add the contact information of the persons designated to receive <br />notice on its behalf by notice given (effective upon the giving of such notice) as provided in <br />this subsection. <br /> <br />O. No Waiver. The waiver of any rights conferred hereunder shall be effective only if made by <br />written instrument executed by the waiving Party or Parties. The waiver by any Party of any <br />breach of this Agreement shall not be deemed to be or construed as a waiver of any other <br />breach, whether prior, subsequent, or contemporaneous, nor shall such waiver be deemed to <br />be or construed as a waiver by any other Party. <br />P. Preservation of Privilege. Nothing contained in this Agreement or any Consent Judgment, <br />and no act required to be performed pursuant to this Agreement or any Consent Judgment, is <br />intended to constitute, cause, or effect any waiver (in whole or in part) of any attorney-client <br />privilege, work product protection, or common interest/joint defense privilege, and each <br />Party agrees that it shall not make or cause to be made in any forum any assertion to the <br />contrary. <br />Q. Successors. This Agreement shall be binding upon, and inure to the benefit of, Janssen and <br />its respective successors and assigns. Janssen shall not sell the majority of its voting stock or <br />substantially all its assets without obtaining the acquiror’s agreement that it will constitute a <br />successor with respect to Janssen’s obligations under this Agreement. <br />R. Modification, Amendment, Alteration. This Agreement may be modified, amended, or <br />altered by a written agreement of the Parties or, in the case of the Consent Judgment, by
The URL can be used to link to this page
Your browser does not support the video tag.